The U.S. Food and Drug Administration approved Roche’s Enspryng for the central nervous system disorder neuromyelitis optica, putting the Swiss drugmaker head-to-head with Alexion’s Soliris in a costly treatment area.

The U.S. Food and Drug Administration approved Viela Bio’s Uplizna (inebilizumab-cdon) for adults with neuromyelitis optica spectrum disorder who are anti-AQP4 antibody positive.

Powered by Xconomy, November 2019’s What’s Next in Neuroscience Therapies event brought together scientists, entrepreneurs and biotech executives at the Hyatt Regency San Francisco to discuss their work developing next-generation neuroscience therapies and technologies in areas such as spinal-cord injuries, precision mental health, dementia and Alzheimer’s disease.

The online publication NEO.LIFE pointed to seven areas where biotech companies and researchers have significant potential to “dramatically reshape our concept of what it means to be human.”

Doctors in Kentucky reported that two of four paralyzed patients were able to walk again with limited assistance after treatment with electrical stimulation to the portion of the spinal cord cut off from the brain, combined with intense physical therapy.

Prescriptions for nerve pain medicines like Neurontin and Lyrica more than tripled in recent years, driven by increased use among chronically ill older adults and patients already taking opioids, a U.S. study suggests.

Despite a temporary halt of an experimental spinal cord implant trial following a patient death, InVivo Therapeutics is doubling down and focusing its financial resources on the treatment by initiating a strategic restructuring that includes cutting nearly 40 percent of its workforce.

Beleaguered PixarBio Corporation slashed the company’s workforce by half and moved its operations from Massachusetts to New Hampshire. PixarBio revealed its moves in a July 2017 filing with the U.S. Securities and Exchange Commission.

The U.S. FDA approved Spinraza as the first drug to treat children and adults with spinal muscular atrophy (SMA), a rare and often fatal genetic disease.

Biogen and Ionis Pharma announced that Spinraza (nusinersen) met its primary endpoint in its Phase III trial in later-onset spinal muscular atrophy (SMA).